Forced expression of HLA-DM at the surface of dendritic cells increases loading of synthetic peptides on MHC class II molecules and modulates T cell responses

Journal of Immunology

Volumn 187, Issue 1, 2011, Pages 74-81

  Pezeshki, Abdul Mohammad ^a   Côté, Marie Hélène ^a   Azar, Georges A ^a   Routy, Jean Pierre ^b   Boulassel, Mohamed Rachid ^b   Thibodeau, Jacques ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

^b ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTYLGLYCYLSERYLTHREONYLASPARTYLTYROSYLGLYCYLISOLEUCYLLEUCYLGLUTAMINYLISOLEUCYLASPARAGINYLSERYLARGININE; HLA DM ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROPYLLYSYLTYROSYLVALYLLYSYLGLUTAMINYLASPARAGINYLTHREONYLLEUCYLLYSYLALANYLTHREONINE; SYNTHETIC PEPTIDE; THREONYLGLYCYLARGINYLMETHIONYLLEUCYLGLYCYLTHREONYLHISTIDINYLTHREONYLMETHIONYLGLUTAMYLVALYLTHREONYLVALYLTYROSYLHISTIDINE; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CELL SURFACE; COMPLEX FORMATION; DENDRITIC CELL; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNOMODULATION; LYMPHOCYTE DIFFERENTIATION; MUTANT; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; CANCER VACCINES; CELL LINE; CELL MEMBRANE; COCULTURE TECHNIQUES; DENDRITIC CELLS; EPITOPES, T-LYMPHOCYTE; HEK293 CELLS; HELA CELLS; HLA-D ANTIGENS; HUMANS; JURKAT CELLS; LYSOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; PEPTIDES; PROTEIN SORTING SIGNALS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC;

EID: 79960431418     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002747     Document Type: Article

References (45)

1. Kennedy, R., and E. Celis. 2008. Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol. Rev. 222: 129-144.
2. Knutson, K. L., and M. L. Disis. 2005. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol. Immunother. 54: 721-728.
3. Ohkuri, T., D. Wakita, K. Chamoto, Y. Togashi, H. Kitamura, and T. Nishimura. 2009. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br. J. Cancer 100: 1135-1143.
4. Khong, H. T., J. C. Yang, S. L. Topalian, R. M. Sherry, S. A. Mavroukakis, D. E. White, and S. A. Rosenberg. 2004. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J. Immunother. 27: 472-477.
5. Tuyaerts, S., J. L. Aerts, J. Corthals, B. Neyns, C. Heirman, K. Breckpot, K. Thielemans, and A. Bonehill. 2007. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol. Immunother. 56: 1513-1537.
6. Denzin, L. K., and P. Cresswell. 1995. HLA-DM induces CLIP dissociation from MHC class II a b dimers and facilitates peptide loading. Cell 82: 155-165.
7. Lindstedt, R., M. Liljedahl, A. Péléraux, P. A. Peterson, and L. Karlsson. 1995. The MHC class II molecule H2-M is targeted to an endosomal compartment by a tyrosine-based targeting motif. Immunity 3: 561-572.
8. Figdor, C. G., I. J. de Vries, W. J. Lesterhuis, and C. J. Melief. 2004. Dendritic cell immunotherapy: mapping the way. Nat. Med. 10: 475-480.
9. Sherman, M. A., D. A. Weber, E. A. Spotts, J. C. Moore, and P. E. Jensen. 1997. Inefficient peptide binding by cell-surface class II MHC molecules. Cell. Immunol. 182: 1-11.
10. Lovitch, S. B., Z. Pu, and E. R. Unanue. 2006. Amino-terminal flanking residues determine the conformation of a peptide-class II MHC complex. J. Immunol. 176: 2958-2968.
11. Santambrogio, L., A. K. Sato, G. J. Carven, S. L. Belyanskaya, J. L. Strominger, and L. J. Stern. 1999. Extracellular antigen processing and presentation by immature dendritic cells. Proc. Natl. Acad. Sci. USA 96: 15056-15061.
12. Arndt, S. O., A. B. Vogt, S. Markovic-Plese, R. Martin, G. Moldenhauer, A. Wölpl, Y. Sun, D. Schadendorf, G. J. Hämmerling, and H. Kropshofer. 2000. Functional HLA-DM on the surface of B cells and immature dendritic cells. EMBO J. 19: 1241-1251. (Pubitemid 30151020)
13. Wong, S. H., L. Santambrogio, and J. L. Strominger. 2004. Caspases and nitric oxide broadly regulate dendritic cell maturation and surface expression of class II MHC proteins. Proc. Natl. Acad. Sci. USA 101: 17783-17788.
14. Herskovits, J. S., C. C. Burgess, R. A. Obar, and R. B. Vallee. 1993. Effects of mutant rat dynamin on endocytosis. J. Cell Biol. 122: 565-578.
15. Bellemare-Pelletier, A., J. Tremblay, S. Beaulieu, M. R. Boulassel, J. P. Routy, B. Massie, R. Lapointe, and J. Thibodeau. 2005. HLA-DO transduced in human monocyte-derived dendritic cells modulates MHC class II antigen processing. J. Leukoc. Biol. 78: 95-105.
16. Brunet, A., A. Samaan, F. Deshaies, T. J. Kindt, and J. Thibodeau. 2000. Functional characterization of a lysosomal sorting motif in the cytoplasmic tail of HLA-DObeta. J. Biol. Chem. 275: 37062-37071.
17. Khalil, H., F. Deshaies, A. Bellemare-Pelletier, A. Brunet, A. Faubert, G. A. Azar, and J. Thibodeau. 2002. Class II transactivator-induced expression of HLA-DO(b) in HeLa cells. Tissue Antigens 60: 372-382. (Pubitemid 36020794)
18. Hewitt, C. R. A., J. R. Lamb, J. Hayball, M. Hill, M. J. Owen, and R. E. O'Hehir. 1992. Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor. J. Exp. Med. 175: 1493-1499.
19. Son, Y. I., S. Egawa, T. Tatsumi, R. E. Redlinger, Jr., P. Kalinski, and T. Kanto. 2002. A novel bulk-culture method for generating mature dendritic cells from mouse bone marrow cells. J. Immunol. Methods 262: 145-157. (Pubitemid 34450739)
20. van Lith, M., M. van Ham, A. Griekspoor, E. Tjin, D. Verwoerd, J. Calafat, H. Janssen, E. Reits, L. Pastoors, and J. Neefjes. 2001. Regulation of MHC class II antigen presentation by sorting of recycling HLA-DM/DO and class II within the multivesicular body. J. Immunol. 167: 884-892. (Pubitemid 32660844)
21. Walseng, E., O. Bakke, and P. A. Roche. 2008. Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway. J. Biol. Chem. 283: 14717-14727.
22. Newton-Nash, D. K., and D. D. Eckels. 1993. Differential effect of polymorphism at HLA-DR1 b-chain positions 85 and 86 on binding and recognition of DR1-restricted antigenic peptides. J. Immunol. 150: 1813-1821.
23. Stumptner-Cuvelette, P., S. Morchoisne, M. Dugast, S. Le Gall, G. Raposo, O. Schwartz, and P. Benaroch. 2001. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. Proc. Natl. Acad. Sci. USA 98: 12144-12149.
24. Busch, R., I. Y. Vturina, J. Drexler, F. Momburg, and G. J. Hämmerling. 1995. Poor loading of major histocompatibility complex class II molecules with endogenously synthesized short peptides in the absence of invariant chain. Eur. J. Immunol. 25: 48-53.
25. Kropshofer, H., A. B. Vogt, G. Moldenhauer, J. Hammer, J. S. Blum, and G. J. Hämmerling. 1996. Editing of the HLA-DR-peptide repertoire by HLA-DM. EMBO J. 15: 6144-6154.
26. Falk, K., J. M. Lau, L. Santambrogio, V. M. Esteban, F. Puentes, O. Rotzschke, and J. L. Strominger. 2002. Ligand exchange of major histocompatibility complex class II proteins is triggered by H-bond donor groups of small molecules. J. Biol. Chem. 277: 2709-2715.
27. Marin-Esteban, V., K. Falk, and O. Rötzschke. 2004. "Chemical analogues" of HLA-DM can induce a peptide-receptive state in HLA-DR molecules. J. Biol. Chem. 279: 50684-50690.
28. Röhn, T. A., M. Boes, D. Wolters, S. Spindeldreher, B. Müller, H. Langen, H. Ploegh, A. B. Vogt, and H. Kropshofer. 2004. Upregulation of the CLIP self peptide on mature dendritic cells antagonizes T helper type 1 polarization. Nat. Immunol. 5: 909-918.
29. Chaturvedi, P., R. Hengeveld, M. A. Zechel, E. Lee-Chan, and B. Singh. 2000. The functional role of class II-associated invariant chain peptide (CLIP) in its ability to variably modulate immune responses. Int. Immunol. 12: 757-765.
30. Chen, T. R. 1987. Cytogenetics of somatic cell hybrids. II. Modal karyotypes and mosaicism in mouse mutant cell lines: LM(tk-), A9, and Rag. Cancer Genet. Cytogenet. 24: 95-107.
31. Weenink, S., H. Averdunk, T. Boston, V. Boswarva, J. C. Guery, L. Adorini, E. Mellins, J. McCluskey, and A. M. Gautam. 1997. Impaired antigen presentation by murine I-Ad class II MHC molecules expressed in normal and HLA-DM-defective human B cell lines. Int. Immunol. 9: 889-896.
32. Dieckmann, D., E. S. Schultz, B. Ring, P. Chames, G. Held, H. R. Hoogenboom, and G. Schuler. 2005. Optimizing the exogenous antigen loading of monocyte-derived dendritic cells. Int. Immunol. 17: 621-635.
33. Busch, R., G. Strang, K. Howland, and J. B. Rothbard. 1990. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int. Immunol. 2: 443-451.
34. Nygard, N. R., K. S. Giacoletto, C. Bono, J. Gorka, S. Kompelli, and B. D. Schwartz. 1994. Peptide binding to surface class II molecules is the major pathway of formation of immunogenic class II-peptide complexes for viable antigen presenting cells. J. Immunol. 152: 1082-1093.
35. Pathak, S. S., and J. S. Blum. 2000. Endocytic recycling is required for the presentation of an exogenous peptide via MHC class II molecules. Traffic 1: 561-569.
36. Mukherjee, R., P. Chaturvedi, E. Lee-Chan, and B. Singh. 2008. Exogenous CLIP localizes into endocytic compartment of cells upon internalization: implications for antigen presentation by MHC class II molecules. Mol. Immunol. 45: 2166-2176.
37. Krogsgaard, M., J. B. Huppa, M. A. Purbhoo, and M. M. Davis. 2003. Linking molecular and cellular events in T-cell activation and synapse formation. Semin. Immunol. 15: 307-315.
38. Chamuleau, M. E., Y. Souwer, S. M. Van Ham, A. Zevenbergen, T. M. Westers, J. Berkhof, C. J. Meijer, A. A. van de Loosdrecht, and G. J. Ossenkoppele. 2004. Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome. Cancer Res. 64: 5546-5550.
39. Jastaniah, W. A., A. J. Alessandri, G. S. Reid, and K. R. Schultz. 2006. HLA-DM expression is elevated in ETV6-AML1 translocation-positive pediatric acute lymphoblastic leukemia. Leuk. Res. 30: 487-489.
40. Oldford, S. A., J. D. Robb, D. Codner, V. Gadag, P. H. Watson, and S. Drover. 2006. Tumor cell expression of HLA-DM associates with a Th1 profile and predicts improved survival in breast carcinoma patients. Int. Immunol. 18: 1591-1602.
41. Constant, S. L., and K. Bottomly. 1997. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu. Rev. Immunol. 15: 297-322.
42. Riberdy, J. M., J. R. Newcomb, M. J. Surman, J. A. Barbosa, and P. Cresswell. 1992. HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides. Nature 360: 474-477.
43. Chou, C. L., S. Mirshahidi, K. W. Su, A. Kim, K. Narayan, S. Khoruzhenko, M. Xu, and S. Sadegh-Nasseri. 2008. Short peptide sequences mimic HLA-DM functions. Mol. Immunol. 45: 1935-1943.
44. Humphreys, R. E., S. Adams, G. Koldzic, B. Nedelescu, E. von Hofe, and M. Xu. 2000. Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. Vaccine 18: 2693-2697. (Pubitemid 30211577)
45. Nicholson, M. J., B. Moradi, N. P. Seth, X. Xing, G. D. Cuny, R. L. Stein, and K. W. Wucherpfennig. 2006. Small molecules that enhance the catalytic efficiency of HLA-DM. J. Immunol. 176: 4208-4220.